ArticleClinical cancer research : an official journal of the American Association for Cancer Research2014
Tumor growth rate is an early indicator of antitumor drug activity in phase I clinical trials.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04722406 (Tumor Growth Rate), which is not on this map. Cited by 98 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Tumor Growth Rate (TGR) as an Early Predictor of Clinical Outcomes in Advanced Non-small Cell Lung Cancer Treated With PD-1 Axis Inhibitors.
Who cites it
98 citing papers in PubMed, 2 syntheses or guidelines pooled it, 173 citations in OpenAlex.
- The Antiproliferative Role of Lanreotide in Controlling Growth of Neuroendocrine Tumors: A Systematic Review.The oncologist · 2017Pooled it
- Systematic review and meta-analysis of phase I/II targeted therapy combined with radiotherapy in patients with glioblastoma multiforme: quality of report, toxicity, and survival.Journal of neuro-oncology · 2015Pooled it
- Pembrolizumab alone and pembrolizumab plus chemotherapy in previously treated, extrapulmonary poorly differentiated neuroendocrine carcinomas.British journal of cancer · 2023Trial
- A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Trial
- Role of 3D volume growth rate for drug activity evaluation in meningioma clinical trials: the example of the CEVOREM study.Neuro-oncology · 2021Trial
- A Randomized Phase 2 Study of Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma.International journal of radiation oncology, biology, physics · 2021Trial
- A Phase II Study of Dovitinib in Patients with Recurrent or Metastatic Adenoid Cystic Carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2017Trial
- Accurate detection of tumor clonality and ongoing expansion mode from genomic data.bioRxiv : the preprint server for biology · 2026Article
- First-in-human evidence of multidrug resistance reversal in solid tumors: a cohort analysis of carbon nanoparticles‑Fe(II) complex trials.BMC cancer · 2026Article
- Investigation of MicroRNAs as predictors of radioligand therapy response in gastroenteropancreatic neuroendocrine tumours.Scientific reports · 2026Article
- Tumor Growth Rate Predicts Pathological Outcomes in Breast Fibroepithelial Tumors: A Pilot Study and Review of Literature.Cancers · 2026Article
- Spatially resolving cancer: from cell states to therapy.Trends in cancer · 2026Review
- Tumor Growth Rate in Neuroendocrine Neoplasms: An Additional Tool for Treatment Strategies?Medicina (Kaunas, Lithuania) · 2025Review
- Evaluation of the Safety, Pharmacokinetics, and Antitumor Activity of Tusamitamab Ravtansine in Patients With Nonsquamous NSCLC With High or Moderate Expression of Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5.JTO clinical and research reports · 2025Article
- Locoregional progression and surgical indications in stage IV asymptomatic SI-NETs.Endocrine-related cancer · 2025Article
- High intensity forced ultrasound-driven ferroptosis as a strategy for anti-tumor immune priming.Acta pharmaceutica Sinica. B · 2025Article
- Efficacy assessment in phase I clinical trials: endpoints and challenges.Annals of oncology : official journal of the European Society for Medical Oncology · 2025Review
- Predominance of hyperprogression in mucosal melanoma during anti-PD-1 monotherapy treatment.The oncologist · 2025Article
- Neuroendocrine tumours and pregnancy: Real-world data from an European Neuroendocrine Tumour Centre of Excellence.Journal of neuroendocrinology · 2025Article
- Binary classification of copy number alteration profiles in liquid biopsy with potential clinical impact in advanced NSCLC.Scientific reports · 2024Article
38 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
12 authors at 5 institutions in 2 countries.
Funding
Abstract
purposeResponse Evaluation Criteria in Solid Tumors (RECIST) evaluation does not take into account the pretreatment tumor kinetics and may provide incomplete information about experimental drug activity. Tumor growth rate (TGR) allows for a dynamic and quantitative assessment of the tumor kinetics. How TGR varies along the introduction of experimental therapeutics and is associated with outcome in phase I patients remains unknown. EXPERIMENTAL
designMedical records from all patients (N = 253) prospectively treated in 20 phase I trials were analyzed. TGR was computed during the pretreatment period (reference) and the experimental period. Associations between TGR, standard prognostic scores [Royal Marsden Hospital (RMH) score], and outcome [progression-free survival (PFS) and overall survival (OS)] were computed (multivariate analysis).
resultsWe observed a reduction of TGR between the reference versus experimental periods (38% vs. 4.4%; P < 0.00001). Although most patients were classified as stable disease (65%) or progressive disease (25%) by RECIST at the first evaluation, 82% and 65% of them exhibited a decrease in TGR, respectively. In a multivariate analysis, only the decrease of TGR was associated with PFS (P = 0.004), whereas the RMH score was the only variable associated with OS (P = 0.0008). Only the investigated regimens delivered were associated with a decrease of TGR (P < 0.00001, multivariate analysis). Computing TGR profiles across different clinical trials reveals specific patterns of antitumor activity.
conclusionsExploring TGR in phase I patients is simple and provides clinically relevant information: (i) an early and subtle assessment of signs of antitumor activity; (ii) independent association with PFS; and (iii) it reveals drug-specific profiles, suggesting potential utility for guiding the further development of the investigational drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.